Table 4.

Univariate and multivariate analysis with respect to overall survival of 138 TNBC patients with surgery plus adjuvant chemotherapy or 52 TNBC patients with surgery alone

	Patients with chemotherapy (n = 138)							Patients without chemotherapy (n = 52)
	Univarite analysis				Multivariate analysis			Univarite analysis			Multivariate analysis
Parameters	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value	Odds ratio	95% CI	p value	Odds ratio	95% CI	P-value
Ki67 (+) and E-cadherin (-) Negative vs Positive	6.69	2.41 to 18.62	<0.001	5.84	2.03 to 16.76	0.001	1.16	0.41 to 3.28	0.777	0.76	0.20 to 2.94	0.688
E-cadherin Negative vs Positive	0.02	0.00 to 1.16	0.060	0.00	0.00 to 1.98	0.943	1.00	0.32 to 3.16	0.998	1.53	0.44 to 5.36	0.503
Ki67 Negative vs Positive	3.09	1.11 to 8.66	0.032	2.60	0.87 to 7.76	0.086	1.81	0.62 to 5.31	0.282	1.89	0.42 to 8.50	0.407
p53 Negative vs Positive	1.61	0.58 to 4.45	0.361	0.98	0.34 to 2.85	0.975	1.61	0.58 to 4.45	0.361	1.86	0.54 to 6.45	0.327
Stage 1 vs 2, 3, 4	2.56	0.73 to 8.99	0.144	0.15	0.01 to 2.45	0.185	4.22	1.17 to 15.28	0.028	1.28	0.06 to 23.36	0.872
Tumor size ≤ 2 cm vs >2 cm	2.63	0.86 to 8.01	0.089	4.23	0.54 to 33.34	0.171	23.26	1.02 to 10.38	0.046	1.65	0.16 to 16.58	0.670
Lymph node status N0 vs N1, N2, N3	4.69	1.67 to 13.16	0.003	5.71	1.25 to 26.20	0.025	5.63	1.68 to 18.93	0.005	5.10	1.08 to 23.94	0.039
Lymphvascular invasion Negative vs Positive	2.09	0.86 to 5.07	0.103	1.34	0.52 to 3.44	0.548	1.32	0.48 to 3.63	0.597	0.94	0.29 to 3.09	0.922
Nuclear grade 1, 2, vs 3	2.87	0.94 to 8.72	0.063	1.64	0.51 to 5.28	0.405	1.22	0.39 to 3.86	0.732	0.99	0.25 to 3.96	0.988